Efgartigimod IV — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Ad
Phase 2/3 · Generalized Myasthenia Gravis |
ARGX ARGENX SE | Efgartigimod IV |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
|